4.6 Article

IV and Perineural Dexmedetomidine Similarly Prolong the Duration of Analgesia after Interscalene Brachial Plexus Block A Randomized, Three-arm, Triple-masked, Placebo-controlled Trial

Journal

ANESTHESIOLOGY
Volume 124, Issue 3, Pages 683-695

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ALN.0000000000000983

Keywords

-

Categories

Funding

  1. Merit Award Program, Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada

Ask authors/readers for more resources

Background: Perineural and IV dexmedetomidine have each been suggested to prolong the duration of analgesia when administered in conjunction with peripheral nerve blocks. In the first randomized, triple-masked, placebo-controlled trial to date, the authors aimed to define and compare the efficacy of perineural and IV dexmedetomidine in prolonging the analgesic duration of single-injection interscalene brachial plexus block (ISB) for outpatient shoulder surgery. Methods: Ninety-nine patients were randomized to receive ISB using 15 ml ropivacaine, 0.5%, with 0.5 mu g/kg dexmedetomidine administered perineurally (Dex(P) group), intravenously (Dex(IV) group), or none (control group). The authors sequentially tested the joint hypothesis that dexmedetomidine prolongs the duration of analgesia and reduces the 24-h cumulative postoperative morphine consumption. Motor blockade, pain severity, hemodynamic variations, opioid-related side effects, postoperative neurologic symptoms, and patient satisfaction were also evaluated. Results: Ninety-nine patients were analyzed. The duration of analgesia was 10.9 h (10.0 to 11.8 h) and 9.8 h (9.0 to 10.6 h) for the Dex(P) and Dex(IV) groups, respectively, compared with 6.7 h (5.6 to 7.8) for the control group (P < 0.001). Dexmedetomidine also reduced the 24-h cumulative morphine consumption to 63.9 mg (58.8 to 69.0 mg) and 66.2 mg (60.6 to 71.8 mg) for the Dex(P) and Dex(IV) groups, respectively, compared with 81.9 mg (75.0 to 88.9 mg) for the control group (P < 0.001). Dex(IV) was noninferior to Dex(P) for these outcomes. Both dexmedetomidine routes reduced the pain and opioid consumption up to 8 h postoperatively and did not prolong the duration of motor blockade. Conclusion: Both perineural and IV dexmedetomidine can effectively prolong the ISB analgesic duration and reduce the opioid consumption without prolonging motor blockade.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available